TCF7-Modified T Cells for Solid Tumor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Adoptive T cell therapy for solid tumors faces challenges in identifying tumor-specific T cells and reprogramming T cells for effective tumor targeting due to intrinsic tumor diversity and lack of conserved tumor antigens, as well as dysfunctional states of tumor-infiltrating T cells.
Innovation Solution
Modulating TCF7 expression in T cells to confer stem-cell like properties, allowing for the generation of memory stem cells that can persist long-term and differentiate into tumor-reactive effector cells, through genetic modification and reprogramming of T cells to express tumor-reactive TCRs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If polyclonal tumor-infiltrating lymphocytes are used for adoptive transfer, then the therapy can be applied to solid tumors, but the variable degree of tumor-specificity and inconsistent robustness remain
Solution Approach 1:
The patent segments the T cell population by isolating and expanding specific tumor-reactive T cell clones based on their TCR specificity, rather than using heterogeneous polyclonal TILs. This allows selection of T cell populations with consistent and defined anti-tumor activity.
Solution Approach 2:
The patent modifies T cell parameters through genetic engineering to enhance persistence and function. Specifically, T cells are modified to express checkpoint inhibitor proteins (anti-PD-1, anti-CTLA-4) and cytokines (IL-7, IL-15, IL-21) that alter their survival, proliferation, and anti-tumor effector functions, thereby improving reliability.
2Reliability
If T cells are genetically modified to enhance persistence and function, then anti-tumor immunity is improved, but the complexity of the genetic modification process increases
Solution Approach 1:
The patent combines multiple genetic modifications in a single T cell construct, including expression of tumor-reactive TCR, checkpoint inhibitors (anti-PD-1, anti-CTLA-4), and cytokines (IL-7, IL-15, IL-21). This multi-functional approach achieves enhanced persistence and anti-tumor activity while streamlining the manufacturing process.
Solution Approach 2:
The patent creates universal T cell constructs that can target multiple tumor antigens through the TCR and provide multiple functions (persistence, proliferation, cytotoxicity) through combined expression of checkpoint inhibitors and cytokines, making the therapy broadly applicable to different solid tumors.
3Measurement precision
If tumor-reactive T cells are identified and expanded, then specific anti-tumor activity is achieved, but the time and resources required for identification and expansion increase
Solution Approach 1:
The patent performs preliminary action by pre-expanding tumor-infiltrating T cells ex vivo before infusion, allowing sufficient time for selection and expansion of tumor-reactive clones. This preliminary expansion ensures that the infused T cell population has adequate anti-tumor activity while maintaining a manageable timeline for therapy preparation.
Data Source
AI summary
The disclosure provides methods of reprogramming polyclonal T cells to maintain long-term persistence. The disclosure further provides methods of treatment, such as adoptive T cell transfer therapies, that harness Tscms for development of tumor-reactive T cells. In some embodiments, the disclosure provides methods and compositions for positive modulation of the Tscm-producing phenotype, e.g., positive modulation of TCF7 expression. Positive modulation of TCF7 expression allows for maintenance of an increased T number of stem-like T cells capable of both self-renewal and generation of differentiated, cytolytic progeny.